Management Participants

  • Mr. Gokul M. Jaykrishna: Managing Director
  • Mr. Arjun G. Jaykrishna: Chief Executive Officer & Executive Director
  • Mr. Mitesh Patel: Executive Director
  • Mr. Saji Joseph: Company Secretary & Compliance Officer

The call was moderated by Abhishek Mehra from TIL Advisors.

Key Management Announcement

Mr. Gokul Jaykrishna announced that, effective from the last Board meeting, he has stepped down as CEO after an eight-year tenure but will continue as Managing Director. Mr. Arjun Jaykrishna, who has been with the company for seven years and an Executive Director for four to five years, has been appointed as the new CEO to lead the company's day-to-day operations.

Q4 FY26 Financial Performance (Consolidated)

  • Revenue from Operations: ₹144 crores, an increase of 19.4% over Q3 FY26.
  • EBITDA: ₹23 crores, up 122% sequentially (QoQ) and 30.2% year-on-year (YoY).
  • EBITDA Margin: 15.6%, compared to 8.58% in Q3 FY26 and 11.53% in Q4 FY25. This represents an expansion of 702 basis points QoQ and 407 basis points YoY.
  • Profit Before Tax (excluding exceptional items): ₹15 crores, an increase of 64.2% YoY and 467.29% QoQ.
  • Profit After Tax: ₹10.82 crores, compared to ₹6.87 crores in Q4 FY25 (up 57.46% YoY) and ₹2.26 crores in Q3 FY26.
  • Interest Cost: Declined to ₹3.30 crores in Q4, down 14.15% YoY, reflecting ongoing debt reduction.
  • Depreciation: ₹4.65 crores, broadly stable.

Full Year FY26 Financial Performance (Consolidated)

  • Revenue from Operations: ₹535.48 crores against ₹562.36 crores in FY25, a decline of 4.78%.
  • EBITDA (including other income): ₹56.53 crores compared to ₹60.21 crores in FY25, a decline of 6.12%.
  • EBITDA Margin: 10.43% compared to 10.63% in FY25, a slight compression of 21 basis points.
  • Profit Before Tax: ₹25.56 crores against ₹24.98 crores in FY25, a marginal increase of 2.35%.
  • Profit After Tax: ₹17.78 crores, up 5.48% over FY25.

Segment-Wise Operational Performance & Commentary

1. Blue Pigment Business (Standalone)

Q4 FY26 was a strong quarter. Both revenues and profitability improved relative to the preceding quarter.

  • Volume growth was modest; a meaningful portion of the improvement was driven by stronger realizations, supported by elevated raw material prices due to geopolitical volatility.
  • The operating environment remains challenging with elevated raw material costs and global supply chain disruptions.
  • The company is working on internal operational efficiencies expected to contribute to a more durable improvement in the margin profile.
  • The business is positioned to accelerate volume growth as the broader demand environment recovers.
  • The company received a one-time rebate related to renewable energy billing charges, which contributed to a lower power and fuel cost (sub-5% of revenue) in Q4. This is not expected to be sustainable every quarter, though overall power and fuel costs as a percentage are expected to be better than historical levels.
  • Utilization: Operating at high utilization levels (approx. 80-85%). Management does not plan any major CAPEX for capacity expansion but aims to improve volumes incrementally through de-bottlenecking and operational efficiencies.
  • Pricing: Realizations improved in Q4. Prices across the product basket have gone up meaningfully (approx. 20%) due to raw material cost pressure and supply issues. The full benefit of recent price increases is expected to flow into the coming quarters as quarterly contracts are renewed.
  • Peak Potential: Management stated the standalone Blue business has a peak potential of achieving ₹400-odd crore revenue with a 13-14% EBITDA margin (approx. ₹50-55 crore absolute EBITDA).

2. AZO Pigment Business (ATC)

  • The company has continued to grow steadily in volumetric terms despite the challenging environment.
  • The segment achieved EBITDA positivity for the full financial year FY26 and reached cash break-even.
  • Utilization: Current utilization is around 65%. The goal is to reach 75-85% utilization before triggering a capacity expansion.
  • Capacity Expansion: Once utilization reaches 85%, a capacity expansion plan will be triggered. The estimated CAPEX is ₹10-15 crores (primarily for plant & machinery, as civil structure is already in place), which would increase capacity by 1.5x. This is expected to be financed through internal accruals.
  • Exports: Efforts are ongoing to attract larger customers in Europe and the US. A recent visit to the US yielded positive discussions with prospective customers. The reduction in US tariffs has reopened opportunities. The process of customer testing and approval is expected to take time.
  • FY26 Financials: Revenue for FY26 was ₹78 crores with a PBT loss of ₹(2.42) crores. Management is confident of achieving PBT break-even in the coming year.
  • Target Margin: Management's long-term target is to achieve an EBITDA margin of around 13% for the AZO business.

3. API Business (Atlas)

  • The business has delivered consistent volumetric growth with an 18% CAGR over the last three years, though this was not reflected in revenues due to significant price erosion.
  • The 3-year price erosion cycle reversed in Q4 FY26, with an improvement in selling prices observed.
  • The company's backward integration investments at its Chattral plant provided operational stability and supported margins.
  • The segment achieved EBITDA positivity for the full year FY26.
  • Regulatory Update: Progress is being made towards achieving CEP (Certification of Suitability) Certification. Management is confident of obtaining it by the end of FY27 (March 2027), which will support volume growth and access to more profitable export segments.
  • Product Mix: Pregabalin is the dominant molecule, contributing 60-70% of API segment revenue. Other molecules include Amisulpride and Etoricoxib.
  • Pricing: Since the acquisition of Atlas, prices had dropped by 40-45%. From the bottom, prices have increased by around 15%.
  • Utilization: The intermediate plant at Chattral is operating at ~70% utilization. The finished API plant at Chattral is operating at a low utilization of ~30%.
  • Strategy: A key focus is to improve the fixed asset turnover and utilization of the finished API plant at Chattral. Management is considering strategic moves, including potential senior-level hiring for business development, to unlock this capacity.
  • Peak Potential: Management guided that the Atlas business (Chattral facility) can achieve a turnover of ₹250-280 crores at peak utilization without any additional CAPEX, with EBITDA margins of 15-16%.
  • Target Margin: Management's long-term target is to achieve an EBITDA margin of 15-16% for the API business.

Capital Allocation & Balance Sheet

  • The company has been focused on debt reduction. Peak debt reached ₹220 crores during the CAPEX cycle.
  • Interest costs declined by 14.15% YoY in Q4 to ₹3.30 crores, reflecting this deleveraging.
  • Cash flows have been strong across all units.
  • The net profit margin for FY26 was 3.3%. Management acknowledged that the current profitability of the AZO and API subsidiaries is below the levels anticipated at the time of investment due to their early-stage nature and a challenging business cycle.

Outlook and Guidance

  • The global operating environment remains uncertain due to geopolitical volatility, elevated raw material costs, and competitive pressures.
  • Management is confident in maintaining the Q4 FY26 performance levels in Q1 FY27 and believes the structural trend is one of improvement.
  • The company's strategy is to focus on sustainable revenue and bottom-line performance, improving fixed asset turnover in subsidiaries, further reducing debt, and aiming for consolidated growth.
  • The long-term goal is to scale the business to ₹1000 crores in the coming years.